SCROLL
SCROLL
Our promise
We believe in the power of our path — as meaningful as its manifestation.
We want to make visible what lies underneath our efforts, to demonstrate how the progress of oncology care starts from here.
We exist to push humanity forward.
Oncology forward.
Whatever it takes.
People
A community of ambitious people of science.
“Our most precious resources are the scientists. We want to get on the top of the game again – also for them.”
History
A glorious past, embraced with resilience.
“When I remember Nerviano’s golden age with the people that worked there, I always hear them say when we were warriors.”
Location
A place, around which
everyone is tied to.
“Companies come and go, but scientists have been doing research here since ’60s.”
About us
Research and development of personalized therapies for cancer patients
We have a mission. To improve patients’ health through our unwavering commitment to discover, develop and deliver life-changing molecules.
Every day we discover, develop, and create new molecules and new personalized oncology therapeutic strategies to improve the lives of people suffering from cancer.
NMS Group is the largest company in Italy committed to oncology innovation and the only institution able to manage the entire integrated R&D chain: from the first steps of the pre-clinical phase to the packaging of the finished product, thanks to the Group’s subsidiaries that each excels in its field.
Perseverance, Respect, Integrity, Dedication and Empathy, we PRIDE our values.
The international certifications, the continuous interactions with public and private scientific institutions and the strong network of collaborations with the scientific community and other industries are the guarantee of our excellence.
NMS Group
This allows us to guarantee the best at every step of the process: from the research of new molecular targets to preclinical trails, clinical trials, commercial manufactory to packaging of innovative drugs, up to regulatory approvals in various countries and patents granted all over the globe.
DISCOVER MORE
The Group’s subsidiaries are: Nerviano Medical Sciences, Accelera and NerPharMa.
Nerviano Medical
Sciences
Nerviano MS represents the innovative core of our Group and is engaged in the discovery and development of new oncology drugs. Each day, our 130 researchers seek and develop new targeted therapy opportunities to generate highly effective and selective molecules.
DISCOVER MORE
Accelera
Accelera is one of the few Italian companies committed to preclinical research and experimentation. It offers integrated high level services for biotech and pharmaceutical companies, as well as academic Institutes and non-profit organizations at a global level.
DISCOVER MORE
NerPharMa
Nerpharma deals with the development and manufacturing of products, beginning with the formulation of the active ingredient up to packaging, from the management of the clinical distribution chain to the regulatory approvals in the different countries.
DISCOVER MORE
Latest News & Events
Nerviano Medical Sciences signs research agreement with Università del Piemonte Orientale, Faculty of Pharmaceutical Sciences
Nerviano, 28 June 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of Pharmaceutical Sciences in Novara (DSF), as part of the National Operational Programme on Research and Innovation 2014-2020 (Programma Operativo Nazionale (PON) – “RICERCA E INNOVAZIONE” 2014-2020). The Programme is the key instrument with which the Italian government contributes to the improvement of the quality of higher education and the enhancement of research, technological development and innovation.
(Click the title for the complete article)
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer.
Nerviano, 31 May 2022
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer. BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari: Transport Oncophysics. BrYet will collaborate with our strategic production partner NerPharMa, a leading CDMO in oncology, to scale-up the drug substance manufacturing process and the finished product to supply material for clinical programs with potential upside to future world-wide commercial sales. The company’s goal is to start ML-016 clinical trials in the second half of 2023.
(Click the title for the complete article)
European Journal of Cancer this month published an article on the FIH study in patients with solid tumors conducted with the MPS1 compound NMS-01940153E discovered at NMS Srl.
Nerviano, 13 May 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to share the publication on the current issue of the European Journal of Cancer of the first-in-human (FIH) study conducted with the MPS1 inhibitor NMS-01940153E discovered in Nerviano (Schöffski et al.; European Journal of Cancer, Volume 169, 2022).
(Click the title for the complete article)
Latest Events
Latest News
Welcome and Check out our new motion picture!